7-甲基六氢[1,3]恶唑并[3,4-a]吡嗪-3-酮 | 91982-32-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 7-甲基六氢[1,3]恶唑并[3,4-a]吡嗪-3-酮
• 英文名称: 9-Oxo-4-methyl-8-oxa-1,4-diaza-bicyclo<4,3,0>nonan
• 英文别名: 7-methyl-hexahydro-oxazolo[3,4-a]pyrazin-3-one；7-Methylhexahydro-3H-[1,3]oxazolo[3,4-a]pyrazin-3-one；7-methyl-5,6,8,8a-tetrahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-3-one
• CAS: 91982-32-0
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.184
• InChiKey: DLXAVHNRMHRTKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] AMINOTRIAZOLES POUR TRAITER DES MALADIES DÉMYÉLINISANTES
  申请人：VERTEX PHARMA

  公开号：WO2018106646A1

  公开（公告）日：2018-06-14

  The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and (vi) The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

  该发明涉及式(I')的三唑化合物或其药学上可接受的盐，用作脱髓鞘疾病的调节剂：其中A选自(i)、(ii)、(iii)、(iv)、(v)和(vi)所述的组。该发明还提供包括该发明化合物的药学上可接受的组合物，以及在治疗各种脱髓鞘和神经退行性疾病，包括多发性硬化症中使用这些组合物和配套工具的方法。
• [EN] PYRAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] PYRAZOLES POUR LE TRAITEMENT DE MALADIES DÉMYÉLINISANTES
  申请人：VERTEX PHARMA

  公开号：WO2018106641A1

  公开（公告）日：2018-06-14

  The invention relates to triazole compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

  该发明涉及式(I)的三唑化合物或其药学上可接受的盐，用作脱髓鞘疾病的调节剂：该发明还提供包括该发明化合物的药学上可接受的组合物，以及在治疗各种脱髓鞘和神经退行性疾病，包括多发性硬化症中使用这些组合物的方法和工具包。
• [EN] HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLE SULTAME UTILISÉS EN TANT QUE MODULATEURS DE RORC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015104353A1

  公开（公告）日：2015-07-16

  (I) Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X1, X2, X3, X4, Y,, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  化合物的公式I或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11的定义如本文所述。还公开了制备这些化合物的方法，以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20160311817A1

  公开（公告）日：2016-10-27

  Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式I的化合物或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11如本文所定义。还公开了制备这些化合物的方法以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• [EN] HETEROCYCLIC AZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] AZOLES HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE MALADIES DE DÉMYÉLINISATION
  申请人：VERTEX PHARMA

  公开号：WO2018106643A1

  公开（公告）日：2018-06-14

  The invention relates to heterocyclic compounds of formula (I) and (IV) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

  该发明涉及式(I)和(IV)的杂环化合物或其药用盐，用作脱髓鞘疾病的调节剂。该发明还提供包含所述化合物的药用组合物，以及使用这些组合物和配套工具治疗各种脱髓鞘和神经退行性疾病的方法，包括多发性硬化症。